Synchron, Inc.

Based in New York, US, Synchron, Inc. operates as a pioneering neurotechnology company, focusing on brain-computer interface solutions that enable users to control digital devices through thought, enhancing quality of life for those with limited mobility. Synchron, Inc. was founded in 2016 and is headquartered in Brooklyn, US.

The company is known for its innovative approach to neurotechnology, specifically through its brain-computer interface offerings. The founders, Rahul Sharma and Thomas Oxley, have backgrounds in medical technology. In November 2025, Synchron, Inc. raised USD 200 million in series D funding led by Double Point Ventures, with participation from Primary Venture Partners, MetaProp, Human Capital, Grafton Street Partners, Friends & Family Capital, Camber Creek, Battery Ventures, Double Point Ventures, National Reconstruction Fund Corporation, In-Q-Tel, Protocol Labs, Inc.

, K5 Global, Qatar Investment Authority, T. Rx Capital, ARCH Venture Partners, Bezos Expeditions, Khosla Ventures, METIS Innovative, and Neuro Technology Investors. Synchron’s primary offering is the Chiral™, a brain-computer interface (BCI) designed to empower users to control digital devices using their thoughts. This innovative technology employs a minimally invasive endovascular procedure akin to stent placement, allowing it to bypass the need for open brain surgery.

The BCI targets individuals with limited mobility due to neurological conditions, aiming to enhance autonomy and facilitate social connections. The technology is utilized in various applications, such as controlling smart home devices and navigating digital environments, thereby addressing significant challenges faced by users. Synchron's products are primarily marketed in North America and Europe, where there is a growing demand for neurotechnological solutions that improve the quality of life for individuals with disabilities. Synchron's revenue model is centered around the commercialization of its Chiral™ BCI, which is positioned as an investigational device within the healthcare sector.

The firm engages with healthcare providers and research institutions to facilitate clinical trials and generate interest in its technology. Revenue is derived from partnerships with hospitals and rehabilitation centers, where the BCI may be integrated into patient care programs. This model involves direct sales of the device or collaboration agreements that provide access to the technology within specific clinical settings. As the product matures and regulatory approvals are obtained, Synchron may implement subscription or service agreements to support ongoing patient use and software updates associated with the BCI.

The company plans to utilize the November 2025 funding to speed up important clinical trials, prepare for the commercial launch of its brain-computer interface system, and grow engineering and artificial intelligence teams to develop the next generation of brain-computer technology.